Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status

Healthy Clinical Trial

— Switch19  

Official title:

Impact of Genetic Polymorphism on Drug Interactions Involving CYP2C19: Risk of Phenoconversion in Healthy CYP2C19 Fast, Normal and Intermediate Metabolizers Status

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05264142
• Other study ID #: 2022-XXXX
• Status: Recruiting
• Phase: Phase 1
• Start date: April 1, 2022
• Est. completion date: August 31, 2023

Study information

• Verified date: October 2022
• Source: University Hospital, Geneva
• Contact: Youssef Daali, Prof
• Phone: 022395430
• Email: Youssef.daali[@]hcuge.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CYP2C19 is responsible for the metabolism of approximately 10% of drugs currently on the market, including several proton pump inhibitors, clopidogrel, benzodiazepines and some tricyclic antidepressants, including amitriptyline. It is a cytochrome whose activity is characterized by a great variability in the general population. This variability can be explained, in part, by genetic and environmental factors The classification of phenotypes associated with CYP2C19 has evolved over time. Today, five distinct phenotypes are used to characterize this variability: the slow metabolizer (SM) phenotype, the intermediate metabolizer (IM) phenotype, the normal metabolizer (NM) phenotype, the fast metabolizer (RM) phenotype and finally the ultra-fast metabolizer (UM) phenotype. (UM) phenotype. Although directly measurable with test substances, CYP2C19 phenotypes are often assigned on the basis of genotype. They may be impacted by intrinsic (e.g., comorbidities) or extrinsic (e.g., co-medications) factors. Phenoconversion or phenotypic change is the phenomenon by which an individual switches from one phenotype to another due to an environmental influence such as a drug interaction. However, genotype is likely to influence the degree of response to a drug interaction. Vulnerability to phenoconversion therefore differs according to the genotype of the individual. The purpose of our study is to determine whether individuals genetically MR, NM and IM have the same vulnerability to phenoconversion. Thus, the magnitude of the response to CYP2C19 inhibition will be studied in these 3 groups of individuals (NM:*1/*1, RM:*1/*17 and IM:*1/*2-*2/*17). Inhibition will be studied in two steps, using a strong (fluvoxamine) and a weak (voriconazole) inhibitor of CYP2C19.

Description:

Phase 1, open-label, parallel study in healthy volunteers selected according to their genotypic belonging to one of the three study groups. Volunteers are included in the study and go through a buccal swab for genotyping, allowing their allocation into 3 groups according to their CYP2C19 genotype (RM: *1/*17 - NM: *1/*1 - IM: *1/*2 and *2/*17). Following this step, volunteers have an inclusion session to determine if they meet the inclusion and non-exclusion criteria for the study. The included volunteers will participate in three study sessions will take place. Session 1 (control session): administration of 10mg of omeprazole for CYP2C19 phenotyping Session 2: same as session 1 with a prior intake of voriconazole 400 mg (weak inhibitor of CYP2C19 2 hours before omeprazole intake) Session 3: same as session 1 with a prior intake of fluvoxamine (strong CYP2C19 inhibitor, 12 h before and 2 h before taking the omeprazole) At each session, dried blood spot (DBS) samples will be collected before the intake of the omeprazole (T0) and then at 2, 3, 6 and 8 hours after taking the capsule. A wash-out period of minimum 3 days will be observed between session 1 and 2 and of minimum 1 week will be observed between sessions 2 and 3.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: August 31, 2023
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy men and women = 18 years old
• Understanding of French language and able to give a written consent
• Reliable contraception during the whole study, including a barrier method
• CYP2C19 genotype associated to the RM (*1/*17) , NM(*1/*1) AND IM(*1/*2-*2/*17) activity groups

Exclusion Criteria:

• Participation in any other interventional clinical study within 3 months prior to inclusion
• Pregnant or breastfeeding woman
• Any pathologies, use of drugs or food that may affect CYP activity (based on the "drug interactions and cytochromes P450" table published by the service of Clinical Pharmacoloy and Toxicology, HUG and on the investigator's knowledge)
• History of liver transplantation
• Alcohol intake during fluvoxamine intake
• Psychotropic substances use during fluvoxamine intake
• Alteration of hepatic tests (ASAT, ALAT, GGT, BILI) more than 3x normal
• Glomerular filtration rate (GFR) < 60 ml/min/1.73 m2
• Medical history of chronic alcoholism or abuse of psychoactive drugs
• Regular use of psychotropic substances
• Sensitivity to any of the drugs used
• Psychiatric disorders
• Beck Score = 10 (question related to suicide >0)

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Voriconazole 200mg
Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
• FluvoxaMINE 50 Mg Oral Tablet
Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
• Omeprazole 10 MG Oral Tablet
Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.

Locations

Country	Name	City	State
Switzerland	Geneva University Hospitals, HUG	Genève

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Geneva

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phenoconversion rate	The proportion of volunteers in each group who acquire a phenotype switch such as from NM to PM after pre-treatment by voriconazole and fluvoxamine (weak and strong inhibitors, respectively)	2 months
Secondary	AUC assessment	Test drugs and their metabolite AUC measurement in whole capillary blood as well as metabolite /probe AUC ratio and single points metabolic ratios.	1 year
Secondary	CL assessment	Test drugs and their metabolite Cl measurement in whole capillary blood	1 year
Secondary	Cmax assessment	Test drugs and their metabolite Cmax measurement in whole capillary blood	1 year
Secondary	Tmax assessment	Test drugs and their metabolite Tmax measurement in whole capillary blood	1 year